Clorox (CLX) Q4 2025 earnings review
ERP Pull-Forward Masks Underlying Weakness; FY26 Guidance Points to Sluggish Growth
Clorox reported Q4 results that appeared strong on the surface, with a 4% revenue increase and a 58% jump in adjusted EPS. However, these figures were massively inflated by retailers pre-ordering inventory ahead of the company's major ERP system transition, a pull-forward that contributed 13-14 percentage points to sales growth and $0.85-$0.95 to EPS. The underlying business performance was weak, with organic sales declining approximately 5.5%, missing management's prior expectations due to a challenging consumer environment. While Clorox successfully rebuilt gross margins in FY25, the outlook for FY26 is muted. Guidance implies a steep decline in reported results as the inventory build reverses, and points to a sluggish underlying organic sales growth of -1% to +2% and adjusted EPS growth of just 2% to 4%.
🐂 Bull Case
Clorox achieved its goal of rebuilding gross margin to pre-pandemic levels, finishing FY25 at 45.2% (+220 bps YoY). FY26 guidance for underlying margin expansion (flat to +50 bps) shows continued discipline.
The massive ERP implementation, while creating significant short-term noise, is a critical, long-overdue modernization of a 25-year-old system that should unlock long-term efficiencies and support future growth.
The wind-down of the Glad JV with P&G and Clorox's intent to acquire the remaining 20% stake will be accretive, eliminating a royalty-like payment and providing a structural ~50 bps annual boost to gross margin once complete.
🐻 Bear Case
The entire Q4 earnings beat was artificial, driven by pulling sales forward from FY26. The underlying business is declining, and management acknowledged missing their own top-line expectations for the second half of the year.
Excluding the ERP noise, the guidance for -1% to +2% organic sales and +2% to +4% adjusted EPS growth is weak, reflecting sluggish category growth (0-1%) and continued consumer pressure with no clear catalyst for re-acceleration.
Management admitted to execution shortfalls in some businesses, like Kingsford. The massive ERP transition in the U.S. is now in a critical 'stabilization phase,' introducing significant operational risk in H1'26 if 'normal bumpiness' proves to be more severe.
⚖️ Verdict: 🔴
Bearish. The quality of the Q4 beat is extremely low, serving only to mask a deteriorating underlying sales trend and set up a difficult FY26. While the margin story has been impressive, the sluggish forward guidance for both sales and earnings, combined with the execution risk of the largest ERP transition in company history, makes the outlook challenging. The bear case is more compelling.
Key Themes
ERP Transition Creates Massive Noise and Execution Risk
The dominant theme is the distortion caused by the U.S. ERP system go-live. Retailers pulled forward an estimated 3.5-4.0 points of annual sales into Q4 FY25 to build inventory. This will reverse in FY26, creating a 7-8 point headwind to organic sales growth. While management calls this a necessary, long-term investment, the company is now in a multi-week 'stabilization phase' where they are ramping up order processing. Any issues beyond the expected 'normal bumpiness' could disrupt supply and sales in Q1'26.
Underlying Consumer Demand Remains Weak
Management noted that categories slowed in the back half of FY25 amid 'macroeconomic uncertainties' and 'rapidly shifting consumer behaviors'. Underlying organic sales fell ~5.5% in Q4, worse than the ~3% decline they had anticipated in the prior quarter. The FY26 plan is built on an assumption of continued sluggish category growth of just 0% to 1%, indicating no expectation of a near-term recovery in consumer demand.
Sustained Margin Discipline Provides Stability
Despite top-line volatility, Clorox has successfully executed its margin recovery plan, with FY25 gross margin reaching 45.2% (+220 bps YoY). This was the tenth consecutive quarter of YoY expansion, driven by a strong cost savings program. The FY26 guidance for flat to +50 bps of underlying margin expansion (ex-ERP effects) demonstrates that this discipline remains a key financial anchor for the company.
Execution Lapses and Competitive Pressures
The narrative of a tough macro environment is partially contradicted by management's admission of operational missteps. CEO Linda Rendle stated, 'we didn't get it all right,' specifically calling out poor execution on Kingsford during key holidays. The call also highlighted ongoing 'deep discounting' by competitors in the Trash (Glad) and Cat Litter categories, forcing Clorox to increase promotional spending.
Innovation Pipeline Ramping for H2'26
Management is banking on a strong innovation pipeline to help reinvigorate growth in the second half of fiscal 2026. After focusing on building on existing platforms in FY25, the company plans to launch entirely new platforms in H2'26. This is positioned as a key catalyst to improve both category growth and market share performance.
Other KPIs
Stable. The Health and Wellness segment was the standout performer, with its +14% organic growth significantly outpacing the company average of +8% and all other segments. Lifestyle (+3%) and International (+1%) lagged considerably, indicating the underlying business health is not uniform across the portfolio.
Stable. Full-year free cash flow was robust, increasing nearly 60% from $483M in FY24. This represents a healthy conversion rate of about 10.7% of net sales and reflects strong operational cash generation despite the broader challenges.
Down 36% YoY from $266M in Q4'24. Management explained this was due to lapping abnormally high spending last year during the cyberattack recovery. The full-year spend was ~11% of sales, in line with the target for FY26, indicating the quarterly drop was a timing-related contributor to the EPS beat, not a strategic cut.
Guidance
Decelerating. The official guidance is $5.95-$6.30. After removing the negative ERP impact ($0.85-$0.95), the implied underlying growth is just +2% to +4% from the FY25 base of $7.72. This represents a sharp deceleration from the underlying +14% to +15% growth achieved in FY25 (ex-ERP benefit).
Decelerating. The official guidance of down 5% to 9% includes a 7-8 point headwind from the ERP reversal. The underlying guidance of -1% to +2% is a step down from the ~1% underlying growth in FY25 (5% reported organic minus ~4% ERP benefit), reflecting continued category weakness.
Decelerating. The official guidance of down 50 to 100 bps includes a ~100 bps headwind from the ERP reversal. The implied underlying performance is a modest expansion, a significant slowdown from the 170 bps of underlying expansion seen in FY25 (220 bps reported minus 50 bps ERP benefit).
Key Questions
Quantifying the Q4 Underlying Miss
The Q4 underlying sales miss was attributed to a dynamic consumer, but also to execution issues. Can you quantify how much of the miss versus your expectations was due to macro factors versus specific operational shortfalls in segments like Household and Lifestyle?
Drivers of Margin Deceleration
FY26 underlying gross margin guidance of flat to +50bps is a notable deceleration. Given the ~20-25bps structural benefit from the Glad JV buyout in H2, what are the primary offsets preventing a stronger underlying margin expansion next year?
Real-Time ERP Status
The ERP 'go-live' occurred in early July. Can you provide a real-time update on the stabilization phase? Have there been any disruptions to order processing or shipments that have exceeded the 'normal bumpiness' you anticipated?